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Chimeric antigen receptor T-cells (CAR T-cells) have been proposed as a possible treatment for multiple 
oncology indications, showing significantly high response rates in patients which have failed to respond to 
previous treatments. The manufacturing process of these promising products poses challenges inherent to 
autologous therapies. These challenges include: high COG, high labour and high facility footprint requirement. 
This presentation describes a detailed economic analysis of the commercial scale manufacture of multiple CAR 
T-cell products. This analysis was carried out using an advanced decisional tool developed at University College 
London. The case study assesses the cost effectiveness of multiple combinations of technologies for whole 
process manufacture of CAR T-cell products, using different viral vectors under multiple dose size and demand 
scenarios. The key cost drivers across these scenarios were identified through a detailed sensitivity analysis. 
This allowed process performance targets for feasible commercialisation of CAR T-cell products to be set, under 
different reimbursement plans. The case study was also extended to explore the potential cost benefits of 
shortening the cell culture process through process optimisation. Multiple process schedules were explored in 
order to reduce resource requirement and facility footprint, and a detailed NPV analysis was carried out with the 
aim of capturing the potential economic and technical benefits of using different manufacturing strategies over 
several years including: manufacturing technologies, process schedules, viral vectors and facility configurations 
(centralised manufacture vs decentralised manufacture vs hospital site manufacture). 
